Large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung cancer that accounts for roughly 3% of all lung malignancies, yet it punches well above its weight in terms of how quickly it grows and spreads. Most people diagnosed with LCNEC experience the same symptoms that other lung cancers produce: a persistent cough, chest pain, shortness of breath, and sometimes coughing up blood. Because it shares features with both small cell lung cancer and more common non-small cell types, LCNEC sits in a gray zone that makes diagnosis tricky and treatment decisions genuinely debated among oncologists.
How LCNEC Typically Shows Up
LCNEC does not have a unique set of symptoms that distinguishes it from other lung cancers at the time you first notice something wrong. The tumor usually develops in the lung’s periphery, so early-stage disease can be completely silent. When symptoms do appear, they tend to mirror what you would expect from any sizable lung mass: a cough that does not go away, chest discomfort, difficulty breathing, unexplained weight loss, and fatigue. If the tumor grows near an airway, you may cough up blood. If it presses on a nerve or invades the chest wall, pain can become the dominant symptom.
What sets LCNEC apart from more common lung cancers is a higher tendency to spread early. By the time of diagnosis, many patients already have metastases in the brain, liver, bones, or adrenal glands. When the cancer reaches distant organs, symptoms reflect those sites: headaches or neurological changes from brain metastases, bone pain from skeletal involvement, or jaundice and abdominal discomfort from liver disease.
Occasionally, LCNEC produces hormones or hormone-like substances that cause what clinicians call paraneoplastic syndromes. One documented example is the syndrome of inappropriate antidiuretic hormone secretion (SIADH), in which the tumor releases a hormone that causes your body to retain too much water, dangerously diluting the sodium in your blood. A case report described a patient whose sodium level dropped to critically low levels, causing dizziness and memory loss, and whose sodium normalized only after the lung tumor was surgically removed.1PubMed Central. Syndrome of inappropriate antidiuretic hormone secretion in a patient with large cell neuroendocrine carcinoma These hormone-related syndromes are uncommon in LCNEC but worth knowing about because their seemingly unrelated symptoms (confusion, weakness, severe fatigue) can delay the correct diagnosis.
Why Diagnosing LCNEC Is Difficult
Getting a definitive LCNEC diagnosis is one of the trickiest problems in thoracic pathology, and that difficulty has real consequences for treatment. LCNEC is defined under the microscope by large tumor cells arranged in patterns that suggest neuroendocrine differentiation: nests, rosettes, or ribbon-like structures. But small biopsy samples, the kind often obtained through a bronchoscope, frequently do not capture enough tissue to see those patterns clearly.
Pathologists rely heavily on special stains called immunohistochemistry markers to confirm the neuroendocrine nature of the tumor. The World Health Organization criteria require positive staining for at least one neuroendocrine marker, but a study of paired biopsy and surgical specimens found that applying the standard criteria to small biopsies caught only about half of true LCNEC cases. Requiring positive staining for two or more of the three common markers boosted the detection rate to around 93% on biopsy specimens.2PubMed Central. Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens? The practical takeaway is that if LCNEC is suspected but the initial biopsy is inconclusive, getting more tissue through a larger biopsy or surgical resection can make a critical difference.
LCNEC also needs to be distinguished from small cell lung cancer, which it closely resembles in aggression and behavior but differs from in cell size, nuclear features, and certain protein expressions. Compared to small cell lung cancer, LCNEC cells tend to show higher levels of certain proteins including the retinoblastoma protein (pRB), specific keratins, and cell-adhesion molecules.3PubMed. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma These differences matter because the two cancers, despite looking similar on a scan, sometimes respond differently to therapy.
Molecular Subtypes and Why They Matter
One of the most significant advances in understanding LCNEC came from genomic sequencing studies that revealed it is not a single disease. At the molecular level, LCNEC splits into at least two major subtypes and one rare minor subtype, each with a different genetic fingerprint and, potentially, different vulnerabilities to treatment.
The first major subtype looks genetically like small cell lung cancer. These tumors carry mutations in both the TP53 and RB1 genes and sometimes have amplifications of a gene called MYCL. The second major subtype resembles non-small cell lung cancer at the DNA level, lacking the combined TP53/RB1 mutations but carrying mutations commonly found in adenocarcinoma, such as KRAS, STK11, and KEAP1.4Clinical Cancer Research. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets A rare third group carries mutations in the MEN1 gene and has a low overall mutation count, resembling a carcinoid tumor more than either of the high-grade cancers.5PubMed Central. Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy
An independent genomic profiling study confirmed these broad categories and showed that some LCNEC tumors are so transcriptionally similar to small cell lung cancer that the boundary between the two is blurry at the molecular level.6Nature Communications. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors This matters for treatment because a tumor that is genetically “SCLC-like” may respond best to the chemotherapy regimens used for small cell lung cancer, while an “NSCLC-like” tumor might do better with the drugs used for adenocarcinoma. Most centers do not yet routinely test for these subtypes before choosing chemotherapy, but that is changing as the evidence accumulates.
Surgery for Early-Stage Disease
When LCNEC is caught at an early enough stage, surgery to remove the tumor offers the best shot at long-term survival. Complete surgical resection is achieved in a large majority of operable patients. A multi-institutional study found five-year survival rates of about 50% for stage I and 45% for stage II, dropping to around 36% for stage IIIA disease. Surgery outperformed radiation-based alternatives: compared with stereotactic body radiation for stage I disease or chemoradiation for stage II–IIIA, surgical resection was associated with a clear survival advantage.7PubMed Central. Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer
Even after successful surgery, the recurrence rate is high enough that most oncologists recommend follow-up chemotherapy. A European multicenter analysis showed five-year survival of about 61% for stage I, 31% for stage II, and 23% for stage III after resection. Patients who received post-surgical chemotherapy had modestly better five-year survival than those who did not, and this benefit held up in separate analyses of both stage I and stage II patients.8PubMed Central. Prognostic markers in resected large cell neuroendocrine carcinoma: a multicentre retrospective analysis The European Society for Thoracic Surgeons database found a similar trend, with adjuvant chemotherapy reducing the risk of death by roughly a quarter.9European Journal of Cardio-Thoracic Surgery. Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma: results from the European Society for Thoracic Surgeons Lung Neuroendocrine Tumours Retrospective Database
One point of clinical judgment is whether the very earliest tumors (stage IA) need chemotherapy at all. A recent review suggested that for these small, node-negative tumors, the decision should be individualized rather than automatic.10PubMed. Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Review For anything beyond the earliest stage, the evidence leans toward giving platinum-based chemotherapy after surgery.
Chemotherapy for Advanced LCNEC
When LCNEC has spread beyond the reach of a surgeon’s scalpel, chemotherapy becomes the backbone of treatment. But which chemotherapy regimen to use has been one of the most contested questions in thoracic oncology, precisely because LCNEC straddles the line between two cancer families that are treated differently.
The small cell lung cancer approach typically combines a platinum drug (cisplatin or carboplatin) with etoposide. The non-small cell approach often pairs a platinum drug with a taxane (such as paclitaxel or docetaxel) or with pemetrexed. An early multi-institutional study concluded that for advanced LCNEC, treatment modeled on small cell lung cancer regimens was more appropriate than non-small cell regimens.11PubMed. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? That conclusion influenced clinical practice for years and is reflected in current guidelines recommending platinum-etoposide as a standard option.10PubMed. Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Review
The picture is not that simple, though. A Dutch study of advanced LCNEC patients found that those treated with non-small cell regimens containing a taxane actually had longer median survival (about eight and a half months) than those treated with small cell-type regimens (about seven months).12European Respiratory Journal. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? And a more recent real-world analysis found no significant difference in survival between the two chemotherapy approaches at all.13PubMed Central. Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis
The disagreement among studies likely reflects the molecular diversity described earlier. If your LCNEC is genetically “SCLC-like,” the platinum-etoposide combination may be a better fit. If it is “NSCLC-like,” a taxane-based regimen might work as well or better. Without routine molecular subtyping, clinicians are essentially guessing, and the mixed results across studies are the predictable outcome of treating a heterogeneous disease as one entity.
Immunotherapy and Its Growing Role
Immune checkpoint inhibitors, drugs that help the immune system recognize and attack cancer cells, have reshaped the treatment of both small cell and non-small cell lung cancer over the past decade. Their role in LCNEC is still being defined, but early evidence is encouraging.
A real-world study comparing advanced LCNEC patients who received checkpoint inhibitors (at any point in their treatment) to those who did not found that the immunotherapy group had a median survival from diagnosis of about 12.4 months compared with 6.0 months for those who never received immunotherapy. Even after matching the two groups to account for differences in baseline characteristics, the survival advantage persisted.14Journal for ImmunoTherapy of Cancer. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
More recently, researchers examined what happens when checkpoint inhibitors are combined with chemotherapy as the first treatment patients receive. A retrospective study found that adding immunotherapy to front-line chemotherapy extended the median time before the cancer progressed from 6.0 months to 10.5 months, and median overall survival from 11.0 months to 15.0 months, cutting the risk of progression by about half.15PubMed Central. First-line immune checkpoint inhibitors combined with chemotherapy in advanced large-cell neuroendocrine carcinoma of the lung: a real-world retrospective study
A meta-analysis pooling data across multiple studies reported an overall response rate of about 35% for LCNEC patients receiving checkpoint inhibitors, with disease control achieved in roughly 72% of cases. When the combination of immunotherapy plus chemotherapy was compared to chemotherapy alone, the disease control rate was significantly higher with the combination.16Journal of Clinical Oncology. Efficacy of immune checkpoint inhibitors (ICIs) in advanced large cell neuroendocrine carcinoma (LCNEC) of the lung: A systematic review and meta-analysis These are not the dramatic response rates seen in some other cancers, but for a disease with historically limited options, they represent a meaningful step forward. Most oncologists now consider adding a checkpoint inhibitor to first-line chemotherapy a reasonable approach, drawing on the same logic used in extensive-stage small cell lung cancer.
Targeted Therapy and Rare Actionable Mutations
Because LCNEC was long lumped with other high-grade neuroendocrine cancers, the search for targetable gene mutations lagged behind adenocarcinoma. Most LCNEC tumors do not carry the common “druggable” mutations found in lung adenocarcinoma. But occasionally, one does.
A case report described a never-smoking woman with stage IV LCNEC whose tumor harbored an EGFR mutation, the same type of mutation that drives many adenocarcinomas. She was treated with osimertinib, a targeted drug used for EGFR-mutant lung cancer, and achieved a sustained response lasting 20 months before the tumor transformed into small cell lung cancer, a known escape mechanism.17PubMed Central. Case Report: Evolution and targeted therapy of an EGFR-mutant large-cell neuroendocrine carcinoma Cases like this are uncommon but underscore why molecular profiling is important. If a targetable mutation is found, the corresponding drug may buy significant time even in this aggressive cancer.
Among the most promising targeted approaches on the horizon are drugs aimed at a protein called DLL3, which is heavily expressed on many high-grade neuroendocrine tumors including both LCNEC and small cell lung cancer. Tarlatamab, a drug that links DLL3-expressing cancer cells to immune T cells, received FDA approval in 2024 for previously treated extensive-stage small cell lung cancer. An investigational DLL3-targeting agent called obrixtamig showed a response rate of about 25% in early trials, with activity seen in LCNEC patients. Several antibody-drug conjugates targeting DLL3 are also in early development.18Journal of Clinical Oncology. Is a New Era of SCLC, LCNEC Treatments on the Horizon? These are still investigational for LCNEC specifically, but DLL3-directed therapy represents one of the first times drug development has deliberately included LCNEC alongside small cell lung cancer in clinical trials.
What Happens When First-Line Treatment Stops Working
Because LCNEC tends to recur even after initially successful treatment, second-line therapy is a reality for many patients. The options at this stage are limited, and the evidence base is thin. A study examining second-line chemotherapy for LCNEC found that the most commonly used drug was amrubicin, an anthracycline-type agent. Response rates were low, around 8%, and median survival from the start of second-line treatment was about eight months. There was no significant difference in outcomes between LCNEC and small cell lung cancer patients receiving the same second-line drugs, suggesting that the two diseases behave similarly once they relapse.19Scientific Reports. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma
Checkpoint inhibitors may also play a role in the second-line setting, and some of the immunotherapy data described earlier included patients receiving these drugs after prior chemotherapy. Clinical trials evaluating DLL3-targeting agents are actively enrolling patients with previously treated LCNEC, which may eventually open up more effective options beyond traditional chemotherapy.
The Role of Radiation
Radiation therapy in LCNEC serves several distinct roles depending on the clinical scenario. For patients with locally advanced disease who cannot undergo surgery, concurrent chemoradiation is an option, though survival outcomes are generally worse than with surgery when surgery is feasible. After surgery, radiation to the chest may be considered if margins are close or lymph nodes are involved, though there is no strong consensus on this.
One question specific to high-grade neuroendocrine tumors is whether preventive radiation to the brain (prophylactic cranial irradiation, or PCI) makes sense. In small cell lung cancer, PCI is a standard recommendation because the brain is a common site of relapse. For LCNEC, the data are suggestive but not yet conclusive. A subgroup analysis found that PCI appeared to offer survival benefits in LCNEC patients without existing brain metastases, though the results did not reach conventional statistical significance. Whole brain radiation for patients who already had brain metastases, by contrast, did not show a clear survival benefit.20International Journal of Radiation Oncology, Biology, Physics. N/A – Section: Abstract PCI for LCNEC remains an area that needs prospective trials before firm recommendations can be made.
Factors That Shape Prognosis
Stage at diagnosis is the most powerful predictor of how long someone with LCNEC will survive, just as it is with most solid tumors. But within each stage, several factors can shift the outlook. A Korean study of resected LCNEC identified two independent predictors of worse survival: older age (67 and above) and having LCNEC mixed with small cell lung cancer. Patients whose tumors had a small cell component fared dramatically worse, with both dying within a year. Pure LCNEC and LCNEC mixed with non-small cell elements had substantially better one-year survival rates.21PubMed Central. Clinical features and treatment outcomes of resected large cell neuroendocrine carcinoma of the lung
Whether the tumor was completely resected, whether adjuvant chemotherapy was given, and the molecular subtype all influence outcomes as well. The emerging consensus is that LCNEC with an “SCLC-like” molecular profile tends to behave more aggressively, while the “NSCLC-like” subtype may carry a somewhat different risk profile. But because molecular subtyping is not yet routine in most clinical settings, stage and histological subtype remain the most commonly used prognostic markers in practice.
LCNEC Outside the Lungs
Although the lung is by far the most common site, large cell neuroendocrine carcinomas can arise in other organs including the gastrointestinal tract, cervix, bladder, and head and neck region. These extrapulmonary LCNECs are even rarer and less studied than the pulmonary form. They share the same aggressive behavior but present unique diagnostic challenges because the primary site can be hard to identify. In one series, a primary tumor was found in only about 63% of patients with extrapulmonary disease. An elevated level of at least one blood-based tumor marker was seen in 93% of cases. Notably, patients whose cancer was confined to lymph nodes all achieved a cure, suggesting that in select cases the disease can be controlled surgically.22PubMed. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features
Treatment strategies for extrapulmonary LCNEC vary by the organ of origin and can include surgery, chemotherapy, radiation, or some combination. The rarity of these tumors means there are no large randomized trials to guide treatment; clinicians typically draw on the pulmonary LCNEC data and on experience with other high-grade neuroendocrine tumors at the same anatomic site.23PubMed. Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues Accurate pathological classification is critical, because the treatment and prognosis of a high-grade neuroendocrine carcinoma in, say, the colon is quite different from that of a conventional colon adenocarcinoma, even if the two originate in the same organ.
Why Repeat Biopsies and Molecular Testing Are Worth Requesting
One of the more practical lessons from the LCNEC literature is that the tumor can change over time. The case of the EGFR-mutant LCNEC that transformed into small cell lung cancer after 20 months of targeted therapy is one example, but phenotypic shifts can happen in the other direction as well. A tumor initially biopsied as non-small cell carcinoma may show neuroendocrine features at progression, or a tumor with one molecular profile at diagnosis may acquire new mutations during treatment.
For patients living with LCNEC, this means repeat biopsies and molecular profiling at the time of relapse are not just academic exercises. They can reveal new mutations amenable to targeted drugs or confirm a shift in tumor biology that warrants a change in chemotherapy regimen. As DLL3-targeting drugs and other novel agents move toward clinical availability, having an up-to-date molecular portrait of the tumor will become even more important for accessing the right treatment at the right time.